Closing the Gap in Prostate Cancer Care:
A New Global Action Plan

Approximately every 75 seconds, a man loses his life to prostate cancer.1,† Today, the science and knowledge exist to change that, yet with the annual number of new cases projected to more than double by 2040, too many men may still receive suboptimal care.2 The Prostate Cancer Council’s Global Action Plan sets out a practical roadmap to mobilise health systems worldwide to transform patient outcomes across three key areas: diagnosis, treatment and supporting men for life. It reveals why dying from or suffering with the disease should no longer be seen as inevitable and calls for urgent coordinated action to strengthen health systems so they can deliver the modern care every man deserves.


Why Is Prostate Cancer a Growing Global Health Challenge?

Prostate cancer has quietly become the most diagnosed cancer in men in more than half the world’s countries.2 Driven by ageing populations and shifting demographics, the annual number of new cases are projected to reach 2.9 million by 2040.2 Over the same period, global deaths are expected to climb by 85%, claiming around 700,000 lives each year.2

Behind these numbers lies an immense human toll: by 2040, a family somewhere in the world will lose a father, brother, partner or son approximately every 45 seconds.2,§ Yet the Prostate Cancer Council – an independent, multidisciplinary group of leading experts and advocates organised and fully funded by AstraZeneca – emphasises that this trajectory is not inevitable. Rather, it reflects a critical implementation gap between the care that modern medicine makes possible and what health systems actually deliver.

Nowhere is the divide clearer than at the point of diagnosis:

  • Early-stage detection: When prostate cancer is detected early and remains confined to the prostate, five-year survival rates can reach 80% to 90% and now approach 100% in countries such as the United States and South Korea.3
  • Late-stage detection: When disease goes undetected and spreads to distant parts of the body, that figure collapses to around 30% potentially robbing men and their families of precious years together.3
  • Global inequities: In parts of sub-Saharan Africa, where capacity to detect and diagnose prostate cancer is limited, almost half of all men with known-stage prostate cancer are diagnosed with stage IV disease.2,4

For too long, prostate cancer has been accepted as a disease that too many men inevitably die from, suffer through or experience lifelong consequences from. That should no longer be the expectation.

Prostate Cancer Council

What Is the Economic Cost of Prostate Cancer?

The human impact of prostate cancer is matched by an escalating economic and societal toll:


Economic and societal burden at a glance


$624 billion

Estimated global economic cost of the disease between 2020 and 2050.5

Cost escalation

In the UK, late detection sharply increases medical expenditure. Treating stage 4 prostate cancer costs around £127,000 per patient compared with £13,000 for stage 1 disease.6

11 hours weekly

Average unpaid care provided by caregivers of men with advanced prostate cancer.7


Why Do We Need A Global Initiative to Drive Change?

Despite representing one of the primary drivers of male cancer mortality worldwide,1,2 prostate cancer continues to be disproportionately overlooked on the global health agenda:

  • It is currently the only cancer among the world’s top five without a dedicated information page on the World Health Organization website.
  • Furthermore, the €12.3 million budget allocated to the EU’s PRAISE-U prostate cancer screening initiative represents only approximately 0.3% of the €4 billion budget earmarked for Europe’s Beating Cancer Plan.8, #

Encouragingly, however, momentum for change is building:

  • Nine countries have now established national men's health policies9
  • England launched its Men’s Health Strategy in late 202510
  • Canada is preparing to follow suit.11

To build on this progress, the Prostate Cancer Council is calling on the World Health Organization (WHO), Member States, and global stakeholders to formally establish a Global Prostate Cancer Initiative. Sitting alongside the WHO’s existing initiatives for cervical, breast, and childhood cancers, this framework would establish a unified international strategy to support countries in improving prostate cancer prevention, diagnosis, treatment and support.

What Are The Three Priorities For Action In The Global Action Plan?

To deliver on this global vision, the Action Plan outlines three fundamental priorities across the patient pathway:


1. Diagnosis Better and Sooner

The stage at which prostate cancer is caught remains one of the most powerful predictors of a man's future.3 While standard prostate-specific antigen (PSA) tests provide a routine initial indicator12, integrating biomarker tests can provide crucial information about the underlying biology of a man’s cancer, helping inform further investigation, risk assessment and treatment decisions, where supported by clinical guidelines. This informs appropriate risk stratification, sparing men with low-risk disease from unnecessary biopsies and radical treatments (avoiding side effects like incontinence and erectile dysfunction) while swiftly connecting high-risk men to targeted therapies.2,13,14,15,16,17 However, testing practices vary widely geographically. An international survey of physicians across the United States, Europe, Japan and China conducted in 2022 and published in 2025 found that biomarker testing remains highly variable across countries.18

To address this, the Action Plan calls on health systems to accelerate adoption of precision diagnostics and risk-adapted pathways to identify aggressive disease earlier, guide personalised treatment decisions and reduce metastatic presentation.

2. Treat Smarter

The expansion of treatment options available has redefined what is possible following a diagnosis, however, as clinical choices become more sophisticated, multidisciplinary team-driven care expertise becomes essential to ensuring men receive the right treatment for them.

Equally important is ensuring that the patient’s voice sits at the heart of every decision. Different treatments involve different trade-offs, making shared decision-making essential to understanding what matters most to each man and helping him choose the treatment that best reflects his preferences.

The Council calls on health systems to ensure every man receives the right treatment for his disease through multidisciplinary expertise, precision medicine and shared decision-making, delivering high-quality, guideline-concordant care.


We already have the science, the knowledge and the evidence. What is needed now is action to ensure every man can benefit from them.

Prostate Cancer Council

3. Support Men For Life

Treatment is only the beginning of a long journey. A European study found 81% of men report unmet supportive care needs during and after treatment, spanning sexual and psychological health and information needs.19 Rehabilitative measures such as pelvic floor muscle training can help improve functional recovery while nurse-led support programmes can help reduce depression.20,21,22 Furthermore, routine PSA testing can reduce prostate cancer deaths.23 Palliative care must also be reframed as continuous and quality-of-life support throughout the disease journey, rather than being confined to end-of-life care interventions.

To ensure survivorship is treated as a priority rather than an afterthought, the Action Plan calls on health systems to drive universal access to survivorship care, ensuring every man receives structured assessment, personalised care planning and ongoing support for his physical, mental, sexual and social wellbeing.


Changing the Course of the Disease

A man’s odds of surviving prostate cancer should never depend on who he is, where he lives, or when his cancer is found.

The Prostate Cancer Council Action Plan shows that the greatest opportunities to improve prostate cancer outcomes today do not depend on future scientific breakthroughs. The knowledge, diagnostic tools, and supportive frameworks already exist. What is needed now is the global commitment to establish a Global Prostate Cancer Initiative to ensure every man can benefit from them. The choices health systems make today will determine the human and economic impact of prostate cancer for decades to come.

About the Prostate Cancer Council
The Prostate Cancer Council is organised and fully funded by AstraZeneca. The Prostate Cancer Council retained editorial control over the content, findings and recommendations presented in the Global Action Plan. MHP Group provided editorial support funded by AstraZeneca.

†This statement is a calculation based on the number of seconds in a year (31,536,000) divided by the number of deaths (419,849) in 2024. 
§This statement is a calculation based on the number of seconds in a year (31,536,000) divided by the number of deaths expected in 2040 (700,000).
#This statement is a calculation based on the budget allocated of €12.3 million divided by €4 billion which equals 0.3%.




Topics:



You may also like


References

  1. Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026;76(4):e70090. doi:10.3322/caac.70090.
  2. James ND, Tannock I, N’Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683–1722. doi:10.1016/S0140-6736(24)00651-2.
  3. Zhou Y, Zou Y, Shen Q, Li Z, Tan Y, Li H, et al. A global review and perspective on prostate cancer survival: findings from survival studies of cancer registration data. J Natl Cancer Cent. 2026;6(2):175–184. doi:10.1016/j.jncc.2026.01.005.
  4. Seraphin TP, Joko-Fru WY, Manraj SS, Chokunonga E, Somdyala NIM, Korir A, et al. Prostate cancer survival in sub-Saharan Africa by age, stage at diagnosis, and human development index: a population-based registry study. Cancer Causes Control. 2021;32(9):1001-1019. doi:10.1007/s10552-021-01453-x.
  5. Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9(4):465–472. doi:10.1001/jamaoncol.2022.7826.
  6. Prostate Cancer Research. Socio-economic impact of prostate cancer screening [Internet]. London: Prostate Cancer Research; 2024 Nov [Last accessed: 17 Nov 2026]. Available from: https://www.prostate-cancer-research.org.uk/wp-content/uploads/2024/11/PCR_Socioeconomic_Impact_Prostate_Cancer_Screening_Nov24-v1.0.pdf.
  7. Jain R, Seebold R, Weiser J, Smith E, Stevens A, Monga N, et al. Patient, caregiver experiences in metastatic castration resistant prostate cancer: insights from a multi-national survey. Future Oncol. 2025;21(16):2053–2066. doi:10.1080/14796694.2025.2510890.
  8. PRAISE-U PCa [Internet]. [Last accessed: 17 Nov 2026]. Available from: https://health.ec.europa.eu/system/files/2023-08/fs_cancer_praise-u.pdf
  9. Global Action on Men’s Health. National men’s health policies [Internet]. London: Global Action on Men’s Health; [Last accessed: 17 Nov 2026]. Available from: https://gamh.org/national-policies/.
  10. Department of Health and Social Care. Men’s health: a strategic vision for England. CP 1432 [Internet]. London: Department of Health and Social Care; 2025 Nov [Last accessed: 17 Nov 2026]. Available from: https://assets.publishing.service.gov.uk/media/69400f3b5cc812f50aa421df/mens-health-a-strategic-vision-for-england.pdf.
  11. Health Canada. Improving the health of men and boys in Canada [Internet]. Government of Canada; 2026 Nov 2 [Last accessed: 17 Nov 2026]. Available from: https://www.canada.ca/en/health-canada/services/healthy-living/improving-health-men-canada.html.
  12. Bratt O, Auvinen A, Godtman RA, Hellström M, Hugosson J, Lilja H et al. Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps. BMJ Oncology. 2023;2(1):e000039. doi:10.1136/bmjonc-2023-000039.
  13. Hendriks RJ, van der Leest MMG, Israël B, Hannink G, YantiSetiasti A, Cornel EB, et al. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. Prostate Cancer Prostatic Dis. 2021;24(4):1110–1119. doi:10.1038/s41391-021-00367-8.
  14. Auvinen A, Tammela TLJ, Mirtti T, Lilja H, Tolonen T, Kenttämies A, et al. Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial. JAMA. 2024;331(17):1452–1459. doi:10.1001/jama.2024.3841.
  15. Fazekas T, Shim SR, Basile G, Baboudjian M, Kói T, Przydacz M, et al. Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis. JAMA Oncol. 2024;10(6):745-754. doi:10.1001/jamaoncol.2024.0734.
  16. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425-1437. doi:10.1056/NEJMoa1606221.
  17. Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547-1558. doi:10.1056/NEJMoa2214122.
  18. Gratzke C, Aggarwal H, Kim J, Chaignaud H, Oskar S. A cross sectional survey of physicians to understand biomarker testing and treatment patterns in patients with prostate cancer in the USA, EU5, Japan, and China. Eur Urol Open Sci. 2025;71:148–155. doi:10.1016/j.euros.2024.07.113.
  19. Cockle-Hearne J, Charnay-Sonnek F, Denis L, Fairbanks HE, Kelly D, Kav S, et al. The impact of supportive nursing care on the needs of men with prostate cancer: a study across seven European countries. Br J Cancer. 2013;109(8):2121–30. doi:10.1038/bjc.2013.568.
  20. Milios JE, Ackland TR, Green DJ. Pelvic floor muscle training in radical prostatectomy: a randomized controlled trial of the impacts on pelvic floor muscle function and urinary incontinence. BMC Urol. 2019;19(1):116. doi:10.1186/s12894-019-0546-5.
  21. Kannan P, Winser SJ, Choi Ho L, Hei LC, Kin LC, Agnieszka GE, et al. Effectiveness of physiotherapy interventions for improving erectile function and climacturia in men after prostatectomy: a systematic review and meta-analysis of randomized controlled trials. Clin Rehabil. 2019;33(8):1298–1309. doi:10.1177/0269215519840392.
  22. Zhang C, Hong Y, Chen Y, Arbing R, Chen WT, Huang F. Effectiveness of nurse-led mHealth interventions on symptom outcomes in adult patients with cancer: a systematic review and meta-analysis. BMC Nurs. 2025;24(1):1356. doi:10.1186/s12912-025-03981-2.
  23. Roobol MJ, de Vos II, Månsson M, Godtman RA, Talala KM, den Hond E, et al. European study of prostate cancer screening – 23-year follow-up. N Engl J Med. 2025;393(17):1669–1680. doi:10.1056/NEJMoa2503223.

Veeva ID: Z4-90848
Date of preparation: November 2026